"21039" . "Imunoterapie karcinomu prostaty" . . "Bart\u016F\u0148kov\u00E1, Ji\u0159ina" . "Imunoterapie karcinomu prostaty"@cs . . "Imunoterapie karcinomu prostaty"@cs . . "dendritic cells; immunotherapy; cancer immunosurveillance; immune syst\u00E9m; prostate cancer"@en . "1802-4475" . . . "I" . "Karcinom prostaty pat\u0159\u00ED mezi nej\u010Dast\u011Bj\u0161\u00ED n\u00E1dorov\u00E1 onemocn\u011Bn\u00ED u mu\u017E\u016F. V \u010Dasn\u00E9m a lokalizovan\u00E9m stadiu je l\u00E9\u010Diteln\u00FD, ur\u010Dit\u00E9 procento pacient\u016F v\u0161ak relabuje nebo se diagn\u00F3za stanov\u00ED a\u017E v pokro\u010Dilej\u0161\u00EDch stadi\u00EDch, kde jsou l\u00E9\u010Debn\u00E9 mo\u017Enosti limitovan\u00E9. Imunoterapie je krom\u011B klasick\u00E9 hormon\u00E1ln\u00ED terapie, radioterapie a chemoterapie dal\u0161\u00ED perspektivn\u00ED l\u00E9\u010Debnou modalitou v t\u011Bchto stadi\u00EDch. Vznik n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED je mnohastup\u0148ov\u00FD proces komplexn\u00ED povahy, v n\u011Bm\u017E samotn\u00E9 n\u00E1dorov\u00E9 bu\u0148ky p\u0159edstavuj\u00ED heterogenn\u00ED populaci zasazenou do kontextu mikroprost\u0159ed\u00ED nen\u00E1dorov\u00FD ch bun\u011Bk a tk\u00E1n\u00ED tvo\u0159\u00EDc\u00EDch slo\u017Eit\u00FD n\u00E1dorov\u00FD %22ekosyst\u00E9m%22. Imunitn\u00ED syst\u00E9m je schopen kontrolovat r\u016Fst n\u00E1dorov\u00FDch bun\u011Bk v ran\u00FDch stadi\u00EDch vzniku n\u00E1doru. S pokro\u010Dil\u00FDm r\u016Fstem n\u00E1doru jsou imunitn\u00ED mechanizmy v\u00EDcem\u00E9n\u011B paralyzov\u00E1ny a mnohdy na proliferaci n\u00E1dorov\u00FDch bun\u011Bk maj\u00ED paradoxn\u011B podp\u016Frn\u00FD \u00FA\u010Dinek. Aby byla protin\u00E1dorov\u00E1 terapie \u00FAsp\u011B\u0161n\u00E1, mus\u00ED zohled\u0148ovat v\u0161echny komplexn\u00ED aspekty interakce imunitn\u00EDho syst\u00E9mu a n\u00E1dorov\u00FDch bun\u011Bk v\u010Detn\u011B mikroprost\u0159ed\u00ED. V \u010Dl\u00E1nku jsou probr\u00E1ny sou\u010Dasn\u00E9 mo\u017Enosti imunoterapie karcinomu prostaty prepar\u00E1ty, kter\u00E9 postoupily do III. f\u00E1ze klinick\u00FDch studi\u00ED." . "11130" . "3"^^ . "RIV/00216208:11130/14:10293314!RIV15-MSM-11130___" . . "[6110D0AB0E65]" . "4"^^ . . "http://www.onkologiecs.cz/pdfs/xon/2014/01/02.pdf" . "Karcinom prostaty pat\u0159\u00ED mezi nej\u010Dast\u011Bj\u0161\u00ED n\u00E1dorov\u00E1 onemocn\u011Bn\u00ED u mu\u017E\u016F. V \u010Dasn\u00E9m a lokalizovan\u00E9m stadiu je l\u00E9\u010Diteln\u00FD, ur\u010Dit\u00E9 procento pacient\u016F v\u0161ak relabuje nebo se diagn\u00F3za stanov\u00ED a\u017E v pokro\u010Dilej\u0161\u00EDch stadi\u00EDch, kde jsou l\u00E9\u010Debn\u00E9 mo\u017Enosti limitovan\u00E9. Imunoterapie je krom\u011B klasick\u00E9 hormon\u00E1ln\u00ED terapie, radioterapie a chemoterapie dal\u0161\u00ED perspektivn\u00ED l\u00E9\u010Debnou modalitou v t\u011Bchto stadi\u00EDch. Vznik n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED je mnohastup\u0148ov\u00FD proces komplexn\u00ED povahy, v n\u011Bm\u017E samotn\u00E9 n\u00E1dorov\u00E9 bu\u0148ky p\u0159edstavuj\u00ED heterogenn\u00ED populaci zasazenou do kontextu mikroprost\u0159ed\u00ED nen\u00E1dorov\u00FD ch bun\u011Bk a tk\u00E1n\u00ED tvo\u0159\u00EDc\u00EDch slo\u017Eit\u00FD n\u00E1dorov\u00FD %22ekosyst\u00E9m%22. Imunitn\u00ED syst\u00E9m je schopen kontrolovat r\u016Fst n\u00E1dorov\u00FDch bun\u011Bk v ran\u00FDch stadi\u00EDch vzniku n\u00E1doru. S pokro\u010Dil\u00FDm r\u016Fstem n\u00E1doru jsou imunitn\u00ED mechanizmy v\u00EDcem\u00E9n\u011B paralyzov\u00E1ny a mnohdy na proliferaci n\u00E1dorov\u00FDch bun\u011Bk maj\u00ED paradoxn\u011B podp\u016Frn\u00FD \u00FA\u010Dinek. Aby byla protin\u00E1dorov\u00E1 terapie \u00FAsp\u011B\u0161n\u00E1, mus\u00ED zohled\u0148ovat v\u0161echny komplexn\u00ED aspekty interakce imunitn\u00EDho syst\u00E9mu a n\u00E1dorov\u00FDch bun\u011Bk v\u010Detn\u011B mikroprost\u0159ed\u00ED. V \u010Dl\u00E1nku jsou probr\u00E1ny sou\u010Dasn\u00E9 mo\u017Enosti imunoterapie karcinomu prostaty prepar\u00E1ty, kter\u00E9 postoupily do III. f\u00E1ze klinick\u00FDch studi\u00ED."@cs . . "8" . "1" . "Podrazil, Michal" . "Prostate cancer is among the most common cancers in men. It is treatable in the early and localized stage; however, a proportion of patients relapse or the diagnosis is made only in more advanced stages when the therapeutic options are limited. In addition to classic hormonal therapy, radiotherapy, and chemotherapy, immunotherapy is another promising treatment modality in these stages. The development of cancer disease is a multistage process of a comprehensive nature wherein the tumour cells themselves represent a very heterogeneous population put into the context of a microenvironment of non-tumour cells and tissues, thus forming a complex tumour %22ecosystem%22. The immune system is capable of controlling tumour cell growth in the early stages of tumour development. With advanced tumour growth, immune mechanisms become more or less paralysed and, in fact, not infrequently have a promoting effect on tumour cell proliferation. In order to be successful, anticancer therapy must take into consideration all the comprehensive aspects of interaction of the immune system and tumour cells, including the microenvironment. The article deals with the current options of immunotherapy for prostate cancer with agents that have advanced into phase III clinical trials."@en . "5"^^ . . "Imunoterapie karcinomu prostaty" . "Immunotherapy for prostate cancer"@en . . "Kukl\u00EDk, Rostislav" . "RIV/00216208:11130/14:10293314" . . "CZ - \u010Cesk\u00E1 republika" . . . . "Onkologie" . . "\u0160p\u00ED\u0161ek, Radek" . . . "Immunotherapy for prostate cancer"@en . .